Laura Kimball Ravari, MD
Endocrinology, Diabetes & Metabolism · Bossier City, LANPI 1861437543
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,816 of the $164,537 with a category attached, or 84.4%. Novo Nordisk accounts for 70.8% of it on its own, with 55 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,047 payments — averaging $157.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$117K
- Sanofi-aventis U.S. LLC$14K
- AbbVie$12K
- Corcept Therapeutics$9K
- Medtronic$2K
- Lilly USA, LLC$1K
- plus $9K from 50 others
What the payments were for
- Speaking & faculty fees$138,81684%
- Travel & lodging$5,4093%
- Food & beverage$20,00212%
- Education$3100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$52,321
- Ozempic$51,149
- SOLIQUA 100/33$11,136
- Synthroid$10,925
- Korlym$8,126
- Saxenda$2,760
- TOUJEO$2,082
- MINIMED 780G$834
- FARXIGA$250
- EVENITY$250
- NEXLETOL$250
- NEXLIZET$250
- Wegovy$250
- TEPEZZA$250
- TRULICITY$125
- Kerendia$125
- Omnipod$125
- VYEPTI$125
- NATPARA (PARATHYROID HORMONE)$124
- FREESTYLE LIBRE 3$105
How this compares
$164,537 in reported general payments places this provider in the 90th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 11 | $237,483 |
| MycapssaOctreotide Acetate | 24 | $159,877 |
| OzempicSemaglutide | 80 | $93,474 |
| MounjaroTirzepatide | 78 | $90,460 |
| SynthroidLevothyroxine Sodium | 595 | $53,417 |
| JardianceEmpagliflozin | 38 | $38,967 |
| TrulicityDulaglutide | 19 | $35,242 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $28,051 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $21,968 |
| RybelsusSemaglutide | 20 | $21,735 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $21,230 |
| VascepaIcosapent Ethyl | 35 | $14,130 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $13,232 |
| FarxigaDapagliflozin Propanediol | 21 | $11,647 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $11,482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $9,358 | $237,48311 claims |
| Chiesi USA, Inc.Mycapssa | $19 | $159,87724 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,337 | $132,974130 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $116,567 | $123,162129 claims |
| AbbVieSynthroid, Armour Thyroid | $11,524 | $56,377644 claims |
| Boehringer IngelheimJardiance | $259 | $38,96738 claims |
| AstraZenecaFarxiga | $703 | $11,64721 claims |
| IBSA Pharma Inc.Tirosint | $147 | $9,33055 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $107 | $39616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Bossier City
- Mary AlbrittonBossier City$11K
- Derek RainwaterBossier City$4K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
- Lawrence BlondeNew Orleans$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.